Diabetic Gastroparesis Treatment Market size is expected to reach nearly US$ 6.41 Bn. by 2029 with the CAGR of 4.6% during the forecast period. Diabetic gastroparesis is delayed gastric emptying related to diabetes. The condition occurs in patients suffering from both type-1 and type-2 diabetes and is common in female patients suffering from type-2 diabetes. The disease includes delayed emptying of the stomach leading to a series of symptoms like nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heart burn.For example, according to the study, ‘Global Prevalence of Type-2 Diabetes over the forecast period (2023-2029), published by the American Diabetes Association, 500 million people worldwide suffered from type-2 diabetes in 2019.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Easy access to off-label medicines without instructions is expected to boost the growth of the diabetic gastroparesis market. Medications like anti-emetic drugs (oandesteron) are reasonable and easily accessible in developing economies. Also, increasing preference towards OTC medicines to avoid higher expenditures is leading to greater disbursement of drugs through retail pharmacies and drugstores. Measures to support product approval and labeling claims for diabetic gastroparesis treatments are expected to offer profitable growth opportunities for a producer in the global diabetic gastroparesis treatment market. For instance, in Feb 2019, a team of researchers associated with Boston Therapeutics, Inc. stated that the Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to estimate treatment benefit in future diabetic gastroparesis interventional trials. Initiatives of regulatory bodies to issue guidance for the development of drugs for the treatment of diabetic gastroparesis are also expected to support the growth of the diabetic gastroparesis treatment market. For example, in Aug 2019, the U.S. FDA issued guidance that reports FDA’s current references about clinical trial designs and clinical endpoint assessments to support the development of drugs for the treatment of idiopathic and diabetic gastroparesis. The absence of clinical evidence on upgrading offered by prescription drugs is expected to hamperthe growth of the global diabetic gastroparesis treatment market. Metoclopramide, domperidone, and erythromycin are used for the treatment of diabetic gastroparesis. On the other hand, approvals of these drugs are inconsistent across countries, leading to the absence of accessibility of consistent patient progress data because ofthe administration of these drugs. There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is mainly due to the early termination of clinical trials or the failure of drugs to meet statistically important endpoints. Such as, in Aug2018, Dartmouth-Hitchcock Medical Center terminated the randomized, double-blind, placebo-controlled trial of promethazine for treatment of diabetic gastroparesis, conducted in collaboration with the American College of Gastroenterology, because ofa shortage of recruitment. Region-wise, the global diabetic gastroparesis treatment market has been segmented into Latin America, North America, Europe,Asia Pacific, the Middle East, and Africa. The diabetic gastroparesis treatment market in North America is expected to hold the largest market share of the total market in the future. This is mainly because of advancements in the diabetic care sector of the US. The objective of the report is to present a comprehensive analysis of the Global Diabetic Gastroparesis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Diabetic Gastroparesis Treatment Market dynamics, structure by analyzing the market segments and project the Global Diabetic Gastroparesis Treatment Market size. Clear representation of competitive analysis of key players By Therapeutics, price, financial position, product portfolio, growth strategies, and regional presence in the Global Diabetic Gastroparesis Treatment Market make the report investor’s guide.
Scope of the Global Diabetic Gastroparesis Treatment Market: Inquire before buying
Global Diabetic Gastroparesis Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 4.68 Bn. Forecast Period 2023 to 2029 CAGR: 4.6% Market Size in 2029: US $ 6.41 Bn. Segments Covered: by Indication Compensated Gastroparesis Gastric Failure by Treatment Medication Surgery by Distribution Channel Hospital Pharmacies Retail Pharmacies Others by Drugs Gastroprokinetic Agents Antiemetic Agents Botulinum Toxin Others by Route of Administration Oral Injectable by End Users Hospitals Homecare Specialty Clinics Others Global Diabetic Gastroparesis Treatment Market, By Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key players operating in the Global Diabetic Gastroparesis Treatment Market
1. Theravance Biopharma 2. Allergan 3. GlaxoSmithKline plc 4. Endologic 5. Evoke Pharma 6. Takeda Pharmaceutical Company Limited 7. Eli Lilly and Company 8. Vanda Pharmaceuticals 9. F. Hoffmann-La Roche Ltd 10.CINRX 11.Ironwood Pharmaceuticals, Inc 12.ANI Pharmaceuticals, Inc 13.Bausch Health 14.RHYTHM PHARMACEUTICALS, INC 15.Teva Pharmaceutical Industries Ltd 16.WOCKHARDT 17.Fresenius Kabi AG 18.Pfizer Inc 19.Ipca Laboratories Ltd 20.Vintage Labs 21.Others Frequently Asked Questions: 1] What segments are covered in the Global Diabetics Gastroparesis Treatment Market report? Ans. The segments covered in the Market report are based on Treatment, Indication, End-user, and Drugs. 2] Which region is expected to hold the highest share in the Global Diabetics Gastroparesis Treatment Market? Ans. The North American region is expected to hold the highest share in Market. 3] What is the market size of the Global Market by 2029? Ans. The market size of the Global Market by 2029 is expected to reach US$ 6.41 Bn. 4] What is the forecast period for the Global Market? Ans. The forecast period for the Independent Software Vendors (ISVs) Market is 2023-2029. 5] What was the market size of the Global Market in 2022? Ans. The market size of the Global Market in 2022 was valued at US$ 4.68 Bn.
Global Diabetic Gastroparesis Treatment Market
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Diabetic Gastroparesis Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast 6.1. Diabetic Gastroparesis Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast, By Indication Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Diabetic Gastroparesis Treatment Market Value Share Analysis, By Indication Type 7.4. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Indication Type 7.5. Diabetic Gastroparesis Treatment Market Analysis, By Indication Type 7.6. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, By Indication Type 8. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Diabetic Gastroparesis Treatment Market Value Share Analysis, By Treatment 8.4. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Treatment 8.5. Diabetic Gastroparesis Treatment Market Analysis, By Treatment 8.6. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, By Treatment 9. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast, By Drugs 9.1. Introduction and Definition 9.2. Key Findings 9.3. Diabetic Gastroparesis Treatment Market Value Share Analysis, By Drugs 9.4. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Drugs 9.5. Diabetic Gastroparesis Treatment Market Analysis, By Drugs 9.6. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, By Drugs 10. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast, By End-Users 10.1. Introduction and Definition 10.2. Key Findings 10.3. Diabetic Gastroparesis Treatment Market Value Share Analysis, By End-Users 10.4. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, By End-Users 10.5. Diabetic Gastroparesis Treatment Market Analysis, By End-Users 10.6. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, By End-Users 11. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast, By Route of Administration 11.1. Introduction and Definition 11.2. Key Findings 11.3. Diabetic Gastroparesis Treatment Market Value Share Analysis, By Route of Administration 11.4. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Route of Administration 11.5. Diabetic Gastroparesis Treatment Market Analysis, By Route of Administration 11.6. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, By Route of Administration 12. Global Diabetic Gastroparesis Treatment Market Analysis and Forecast, By Distribution Channel 12.1. Introduction and Definition 12.2. Key Findings 12.3. Diabetic Gastroparesis Treatment Market Value Share Analysis, By Distribution Channel 12.4. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Distribution Channel 12.5. Diabetic Gastroparesis Treatment Market Analysis, By Distribution Channel 12.6. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, By Distribution Channel 13. Global Diabetic Gastroparesis Treatment Market Analysis, by Region 13.1. Diabetic Gastroparesis Treatment Market Value Share Analysis, by Region 13.2. Diabetic Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Region 13.3. Diabetic Gastroparesis Treatment Market Attractiveness Analysis, by Region 14. North America Diabetic Gastroparesis Treatment Market Analysis 14.1. Key Findings 14.2. North America Diabetic Gastroparesis Treatment Market Overview 14.3. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Indication Type 14.4. North America Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 14.4.1. Compensated Gastroparesis 14.4.2. Gastric Failure 14.5. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Treatment 14.6. North America Diabetic Gastroparesis Treatment Market Forecast, By Treatment 14.6.1. Medication 14.6.2. Surgery 14.7. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Drugs 14.8. North America Diabetic Gastroparesis Treatment Market Forecast, By Drugs 14.8.1. Gastroprokinetic Agents 14.8.1.1. Metoclopramide 14.8.1.2. Pruclopride 14.8.2. Antiemetic Agents 14.8.2.1. Prochlorperazine 14.8.2.2. Ondansetron 14.8.3. Botulinum Toxin 14.8.4. Others 14.9. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, By End-Users 14.10. North America Diabetic Gastroparesis Treatment Market Forecast, By End-Users 14.10.1. Hospitals 14.10.2. Homecare 14.10.3. Specialty Clinics 14.10.4. Others 14.11. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Route of Administration 14.12. North America Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 14.12.1. Oral 14.12.2. Injectable 14.13. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Distribution Channel 14.14. North America Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Others 14.15. North America Diabetic Gastroparesis Treatment Market Value Share Analysis, by Country 14.16. North America Diabetic Gastroparesis Treatment Market Forecast, by Country 14.16.1. U.S. 14.16.2. Canada 14.17. North America Diabetic Gastroparesis Treatment Market Analysis, by Country 14.18. U.S. Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 14.18.1. Compensated Gastroparesis 14.18.2. Gastric Failure 14.19. U.S. Diabetic Gastroparesis Treatment Market Forecast, By Treatment 14.19.1. Medication 14.19.2. Surgery 14.20. U.S. Diabetic Gastroparesis Treatment Market Forecast, By Drugs 14.20.1. Gastroprokinetic Agents 14.20.1.1. Metoclopramide 14.20.1.2. Pruclopride 14.20.2. Antiemetic Agents 14.20.2.1. Prochlorperazine 14.20.2.2. Ondansetron 14.20.3. Botulinum Toxin 14.20.4. Others 14.21. U.S.Diabetic Gastroparesis Treatment Market Forecast, By End-Users 14.21.1. Hospitals 14.21.2. Homecare 14.21.3. Specialty Clinics 14.21.4. Others 14.22. U.S. Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 14.22.1. Oral 14.22.2. Injectable 14.23. U.S. Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 14.23.1. Hospital Pharmacies 14.23.2. Retail Pharmacies 14.23.3. Others 14.24. Canada Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 14.24.1. Compensated Gastroparesis 14.24.2. Gastric Failure 14.25. Canada Diabetic Gastroparesis Treatment Market Forecast, By Treatment 14.25.1. Medication 14.25.2. Surgery 14.26. Canada Diabetic Gastroparesis Treatment Market Forecast, By Drugs 14.26.1. Gastroprokinetic Agents 14.26.1.1. Metoclopramide 14.26.1.2. Pruclopride 14.26.2. Antiemetic Agents 14.26.2.1. Prochlorperazine 14.26.2.2. Ondansetron 14.26.3. Botulinum Toxin 14.26.4. Others 14.27. Canada Diabetic Gastroparesis Treatment Market Forecast, By End-Users 14.27.1. Hospitals 14.27.2. Homecare 14.27.3. Specialty Clinics 14.27.4. Others 14.28. Canada Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 14.28.1. Oral 14.28.2. Injectable 14.29. Canada Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 14.29.1. Hospital Pharmacies 14.29.2. Retail Pharmacies 14.29.3. Others 14.30. North America Diabetic Gastroparesis Treatment Market Attractiveness Analysis 14.30.1. By Indication Type 14.30.2. By Treatment 14.30.3. By Drugs 14.30.4. By End-Users 14.30.5. By Route of Administration 14.30.6. By Distribution Channel 14.31. PEST Analysis 14.32. Key Trends 14.33. Key Developments 15. Europe Diabetic Gastroparesis Treatment Market Analysis 15.1. Key Findings 15.2. Europe Diabetic Gastroparesis Treatment Market Overview 15.3. Europe Diabetic Gastroparesis Treatment Market Value Share Analysis, By Indication Type 15.4. Europe Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.4.1. Compensated Gastroparesis 15.4.2. Gastric Failure 15.5. Europe Diabetic Gastroparesis Treatment Market Value Share Analysis, By Treatment 15.6. Europe Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.6.1. Medication 15.6.2. Surgery 15.7. Europe Diabetic Gastroparesis Treatment Market Value Share Analysis, By Drugs 15.8. Europe Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.8.1. Gastroprokinetic Agents 15.8.1.1. Metoclopramide 15.8.1.2. Pruclopride 15.8.2. Antiemetic Agents 15.8.2.1. Prochlorperazine 15.8.2.2. Ondansetron 15.8.3. Botulinum Toxin 15.8.4. Others 15.9. EuropeDiabetic Gastroparesis Treatment Market Value Share Analysis, By End-Users 15.10. EuropeDiabetic Gastroparesis Treatment Market Forecast, By End-Users 15.10.1. Hospitals 15.10.2. Homecare 15.10.3. Specialty Clinics 15.10.4. Others 15.11. Europe Diabetic Gastroparesis Treatment Market Value Share Analysis, By Route of Administration 15.12. Europe Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.12.1. Oral 15.12.2. Injectable 15.13. Europe Diabetic Gastroparesis Treatment Market Value Share Analysis, By Distribution Channel 15.14. Europe Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Others 15.15. Europe Diabetic Gastroparesis Treatment Market Value Share Analysis, by Country 15.16. Europe Diabetic Gastroparesis Treatment Market Forecast, by Country 15.16.1. Germany 15.16.2. U.K. 15.16.3. France 15.16.4. Italy 15.16.5. Spain 15.16.6. Russia 15.16.7. Sweden 15.16.8. Norway 15.16.9. Rest of Europe 15.17. Europe Diabetic Gastroparesis Treatment Market Analysis, by Country 15.18. Germany Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.18.1. Compensated Gastroparesis 15.18.2. Gastric Failure 15.19. Germany Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.19.1. Medication 15.19.2. Surgery 15.20. Germany Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.20.1. Gastroprokinetic Agents 15.20.1.1. Metoclopramide 15.20.1.2. Pruclopride 15.20.2. Antiemetic Agents 15.20.2.1. Prochlorperazine 15.20.2.2. Ondansetron 15.20.3. Botulinum Toxin 15.20.4. Others 15.21. Germany Diabetic Gastroparesis Treatment Market Forecast, By End-Users 15.21.1. Hospitals 15.21.2. Homecare 15.21.3. Specialty Clinics 15.21.4. Others 15.22. Germany Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.22.1. Oral 15.22.2. Injectable 15.23. Germany Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.23.1. Hospital Pharmacies 15.23.2. Retail Pharmacies 15.23.3. Others 15.24. U.K. Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.24.1. Compensated Gastroparesis 15.24.2. Gastric Failure 15.25. U.K. Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.25.1. Medication 15.25.2. Surgery 15.26. U.K. Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.26.1. Gastroprokinetic Agents 15.26.1.1. Metoclopramide 15.26.1.2. Pruclopride 15.26.2. Antiemetic Agents 15.26.2.1. Prochlorperazine 15.26.2.2. Ondansetron 15.26.3. Botulinum Toxin 15.26.4. Others 15.27. U.K. Diabetic Gastroparesis Treatment Market Forecast, By End-Users 15.27.1. Hospitals 15.27.2. Homecare 15.27.3. Specialty Clinics 15.27.4. Others 15.28. U.K. Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.28.1. Oral 15.28.2. Injectable 15.29. U.K. Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.29.1. Hospital Pharmacies 15.29.2. Retail Pharmacies 15.29.3. Others 15.30. France Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.30.1. Compensated Gastroparesis 15.30.2. Gastric Failure 15.31. France Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.31.1. Medication 15.31.2. Surgery 15.32. France Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.32.1. Gastroprokinetic Agents 15.32.1.1. Metoclopramide 15.32.1.2. Pruclopride 15.32.2. Antiemetic Agents 15.32.2.1. Prochlorperazine 15.32.2.2. Ondansetron 15.32.3. Botulinum Toxin 15.32.4. Others 15.33. France Diabetic Gastroparesis Treatment Market Forecast, By End-Users 15.33.1. Hospitals 15.33.2. Homecare 15.33.3. Specialty Clinics 15.33.4. Others 15.34. France Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.34.1. Oral 15.34.2. Injectable 15.35. France Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.35.1. Hospital Pharmacies 15.35.2. Retail Pharmacies 15.35.3. Others 15.36. Italy Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.36.1. Compensated Gastroparesis 15.36.2. Gastric Failure 15.37. Italy Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.37.1. Medication 15.37.2. Surgery 15.38. Italy Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.38.1. Gastroprokinetic Agents 15.38.1.1. Metoclopramide 15.38.1.2. Pruclopride 15.38.2. Antiemetic Agents 15.38.2.1. Prochlorperazine 15.38.2.2. Ondansetron 15.38.3. Botulinum Toxin 15.38.4. Others 15.39. Italy Diabetic Gastroparesis Treatment Market Forecast, By End-Users 15.39.1. Hospitals 15.39.2. Homecare 15.39.3. Specialty Clinics 15.39.4. Others 15.40. Italy Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.40.1. Oral 15.40.2. Injectable 15.41. Italy Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.41.1. Hospital Pharmacies 15.41.2. Retail Pharmacies 15.41.3. Others 15.42. Spain Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.42.1. Compensated Gastroparesis 15.42.2. Gastric Failure 15.43. Spain Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.43.1. Medication 15.43.2. Surgery 15.44. Spain Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.44.1. Gastroprokinetic Agents 15.44.1.1. Metoclopramide 15.44.1.2. Pruclopride 15.44.2. Antiemetic Agents 15.44.2.1. Prochlorperazine 15.44.2.2. Ondansetron 15.44.3. Botulinum Toxin 15.44.4. Others 15.45. Spain Diabetic Gastroparesis Treatment Market Forecast, By End-Users 15.45.1. Hospitals 15.45.2. Homecare 15.45.3. Specialty Clinics 15.45.4. Others 15.46. Spain Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.46.1. Oral 15.46.2. Injectable 15.47. Spain Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.47.1. Hospital Pharmacies 15.47.2. Retail Pharmacies 15.47.3. Others 15.48. RussiaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.48.1. Compensated Gastroparesis 15.48.2. Gastric Failure 15.49. RussiaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 15.49.1. Medication 15.49.2. Surgery 15.50. RussiaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 15.50.1. Gastroprokinetic Agents 15.50.1.1. Metoclopramide 15.50.1.2. Pruclopride 15.50.2. Antiemetic Agents 15.50.2.1. Prochlorperazine 15.50.2.2. Ondansetron 15.50.3. Botulinum Toxin 15.50.4. Others 15.51. RussiaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 15.51.1. Hospitals 15.51.2. Homecare 15.51.3. Specialty Clinics 15.51.4. Others 15.52. RussiaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.52.1. Oral 15.52.2. Injectable 15.53. RussiaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.53.1. Hospital Pharmacies 15.53.2. Retail Pharmacies 15.53.3. Others 15.54. SwedenDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.54.1. Compensated Gastroparesis 15.54.2. Gastric Failure 15.55. SwedenDiabetic Gastroparesis Treatment Market Forecast, By Treatment 15.55.1. Medication 15.55.2. Surgery 15.56. SwedenDiabetic Gastroparesis Treatment Market Forecast, By Drugs 15.56.1. Gastroprokinetic Agents 15.56.1.1. Metoclopramide 15.56.1.2. Pruclopride 15.56.2. Antiemetic Agents 15.56.2.1. Prochlorperazine 15.56.2.2. Ondansetron 15.56.3. Botulinum Toxin 15.56.4. Others 15.57. SwedenDiabetic Gastroparesis Treatment Market Forecast, By End-Users 15.57.1. Hospitals 15.57.2. Homecare 15.57.3. Specialty Clinics 15.57.4. Others 15.58. SwedenDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.58.1. Oral 15.58.2. Injectable 15.59. SwedenDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.59.1. Hospital Pharmacies 15.59.2. Retail Pharmacies 15.59.3. Others 15.60. NorwayDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.60.1. Compensated Gastroparesis 15.60.2. Gastric Failure 15.61. NorwayDiabetic Gastroparesis Treatment Market Forecast, By Treatment 15.61.1. Medication 15.61.2. Surgery 15.62. NorwayDiabetic Gastroparesis Treatment Market Forecast, By Drugs 15.62.1. Gastroprokinetic Agents 15.62.1.1. Metoclopramide 15.62.1.2. Pruclopride 15.62.2. Antiemetic Agents 15.62.2.1. Prochlorperazine 15.62.2.2. Ondansetron 15.62.3. Botulinum Toxin 15.62.4. Others 15.63. NorwayDiabetic Gastroparesis Treatment Market Forecast, By End-Users 15.63.1. Hospitals 15.63.2. Homecare 15.63.3. Specialty Clinics 15.63.4. Others 15.64. NorwayDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.64.1. Oral 15.64.2. Injectable 15.65. NorwayDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.65.1. Hospital Pharmacies 15.65.2. Retail Pharmacies 15.65.3. Others 15.66. Rest of Europe Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 15.66.1. Compensated Gastroparesis 15.66.2. Gastric Failure 15.67. Rest of Europe Diabetic Gastroparesis Treatment Market Forecast, By Treatment 15.67.1. Medication 15.67.2. Surgery 15.68. Rest of Europe Diabetic Gastroparesis Treatment Market Forecast, By Drugs 15.68.1. Gastroprokinetic Agents 15.68.1.1. Metoclopramide 15.68.1.2. Pruclopride 15.68.2. Antiemetic Agents 15.68.2.1. Prochlorperazine 15.68.2.2. Ondansetron 15.68.3. Botulinum Toxin 15.68.4. Others 15.69. Rest of EuropeDiabetic Gastroparesis Treatment Market Forecast, By End-Users 15.69.1. Hospitals 15.69.2. Homecare 15.69.3. Specialty Clinics 15.69.4. Others 15.70. Rest Of Europe Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 15.70.1. Oral 15.70.2. Injectable 15.71. Rest Of Europe Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 15.71.1. Hospital Pharmacies 15.71.2. Retail Pharmacies 15.71.3. Others 15.72. Europe Diabetic Gastroparesis Treatment Market Attractiveness Analysis 15.72.1. By Indication Type 15.72.2. By Treatment 15.72.3. By Drugs 15.72.4. By End-Users 15.72.5. By Route of Administration 15.72.6. By Distribution Channel 15.73. PEST Analysis 15.74. Key Trends 15.75. Key Developments 16. Asia Pacific Diabetic Gastroparesis Treatment Market Analysis 16.1. Key Findings 16.2. Asia Pacific Diabetic Gastroparesis Treatment Market Overview 16.3. Asia Pacific Diabetic Gastroparesis Treatment Market Value Share Analysis, By Indication Type 16.4. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.4.1. Compensated Gastroparesis 16.4.2. Gastric Failure 16.5. Asia Pacific Diabetic Gastroparesis Treatment Market Value Share Analysis, By Treatment 16.6. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Treatment 16.6.1. Medication 16.6.2. Surgery 16.7. Asia Pacific Diabetic Gastroparesis Treatment Market Value Share Analysis, By Drugs 16.8. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Drugs 16.8.1. Gastroprokinetic Agents 16.8.1.1. Metoclopramide 16.8.1.2. Pruclopride 16.8.2. Antiemetic Agents 16.8.2.1. Prochlorperazine 16.8.2.2. Ondansetron 16.8.3. Botulinum Toxin 16.8.4. Others 16.9. Asia PacificDiabetic Gastroparesis Treatment Market Value Share Analysis, By End-Users 16.10. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By End-Users 16.10.1. Hospitals 16.10.2. Homecare 16.10.3. Specialty Clinics 16.10.4. Others 16.11. Asia Pacific Diabetic Gastroparesis Treatment Market Value Share Analysis, By Route of Administration 16.12. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.12.1. Oral 16.12.2. Injectable 16.13. Asia Pacific Diabetic Gastroparesis Treatment Market Value Share Analysis, By Distribution Channel 16.14. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.14.1. Hospital Pharmacies 16.14.2. Retail Pharmacies 16.14.3. Others 16.15. Asia Pacific Diabetic Gastroparesis Treatment Market Value Share Analysis, by Country 16.16. Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, by Country 16.16.1. China 16.16.2. India 16.16.3. Japan 16.16.4. South Korea 16.16.5. Australia 16.16.6. Indonesia 16.16.7. Malaysia 16.16.8. Vietnam 16.16.9. Rest of Asia Pacific 16.17. Asia Pacific Diabetic Gastroparesis Treatment Market Analysis, by Country 16.18. China Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.18.1. Compensated Gastroparesis 16.18.2. Gastric Failure 16.19. China Diabetic Gastroparesis Treatment Market Forecast, By Treatment 16.19.1. Medication 16.19.2. Surgery 16.20. China Diabetic Gastroparesis Treatment Market Forecast, By Drugs 16.20.1. Gastroprokinetic Agents 16.20.1.1. Metoclopramide 16.20.1.2. Pruclopride 16.20.2. Antiemetic Agents 16.20.2.1. Prochlorperazine 16.20.2.2. Ondansetron 16.20.3. Botulinum Toxin 16.20.4. Others 16.21. China Diabetic Gastroparesis Treatment Market Forecast, By End-Users 16.21.1. Hospitals 16.21.2. Homecare 16.21.3. Specialty Clinics 16.21.4. Others 16.22. China Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.22.1. Oral 16.22.2. Injectable 16.23. China Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.23.1. Hospital Pharmacies 16.23.2. Retail Pharmacies 16.23.3. Others 16.24. India Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.24.1. Compensated Gastroparesis 16.24.2. Gastric Failure 16.25. India Diabetic Gastroparesis Treatment Market Forecast, By Treatment 16.25.1. Medication 16.25.2. Surgery 16.26. India Diabetic Gastroparesis Treatment Market Forecast, By Drugs 16.26.1. Gastroprokinetic Agents 16.26.1.1. Metoclopramide 16.26.1.2. Pruclopride 16.26.2. Antiemetic Agents 16.26.2.1. Prochlorperazine 16.26.2.2. Ondansetron 16.26.3. Botulinum Toxin 16.26.4. Others 16.27. India Diabetic Gastroparesis Treatment Market Forecast, By End-Users 16.27.1. Hospitals 16.27.2. Homecare 16.27.3. Specialty Clinics 16.27.4. Others 16.28. India Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.28.1. Oral 16.28.2. Injectable 16.29. India Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.29.1. Hospital Pharmacies 16.29.2. Retail Pharmacies 16.29.3. Others 16.30. Japan Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.30.1. Compensated Gastroparesis 16.30.2. Gastric Failure 16.31. Japan Diabetic Gastroparesis Treatment Market Forecast, By Treatment 16.31.1. Medication 16.31.2. Surgery 16.32. Japan Diabetic Gastroparesis Treatment Market Forecast, By Drugs 16.32.1. Gastroprokinetic Agents 16.32.1.1. Metoclopramide 16.32.1.2. Pruclopride 16.32.2. Antiemetic Agents 16.32.2.1. Prochlorperazine 16.32.2.2. Ondansetron 16.32.3. Botulinum Toxin 16.32.4. Others 16.33. Japan Diabetic Gastroparesis Treatment Market Forecast, By End-Users 16.33.1. Hospitals 16.33.2. Homecare 16.33.3. Specialty Clinics 16.33.4. Others 16.34. Japan Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.34.1. Oral 16.34.2. Injectable 16.35. Japan Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.35.1. Hospital Pharmacies 16.35.2. Retail Pharmacies 16.35.3. Others 16.36. South KoreaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.36.1. Compensated Gastroparesis 16.36.2. Gastric Failure 16.37. South KoreaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 16.37.1. Medication 16.37.2. Surgery 16.38. South KoreaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 16.38.1. Gastroprokinetic Agents 16.38.1.1. Metoclopramide 16.38.1.2. Pruclopride 16.38.2. Antiemetic Agents 16.38.2.1. Prochlorperazine 16.38.2.2. Ondansetron 16.38.3. Botulinum Toxin 16.38.4. Others 16.39. South KoreaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 16.39.1. Hospitals 16.39.2. Homecare 16.39.3. Specialty Clinics 16.39.4. Others 16.40. South KoreaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.40.1. Oral 16.40.2. Injectable 16.41. South KoreaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.41.1. Hospital Pharmacies 16.41.2. Retail Pharmacies 16.41.3. Others 16.42. AustraliaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.42.1. Compensated Gastroparesis 16.42.2. Gastric Failure 16.43. AustraliaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 16.43.1. Medication 16.43.2. Surgery 16.44. AustraliaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 16.44.1. Gastroprokinetic Agents 16.44.1.1. Metoclopramide 16.44.1.2. Pruclopride 16.44.2. Antiemetic Agents 16.44.2.1. Prochlorperazine 16.44.2.2. Ondansetron 16.44.3. Botulinum Toxin 16.44.4. Others 16.45. AustraliaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 16.45.1. Hospitals 16.45.2. Homecare 16.45.3. Specialty Clinics 16.45.4. Others 16.46. AustraliaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.46.1. Oral 16.46.2. Injectable 16.47. AustraliaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.47.1. Hospital Pharmacies 16.47.2. Retail Pharmacies 16.47.3. Others 16.48. MalaysiaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.48.1. Compensated Gastroparesis 16.48.2. Gastric Failure 16.49. MalaysiaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 16.49.1. Medication 16.49.2. Surgery 16.50. MalaysiaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 16.50.1. Gastroprokinetic Agents 16.50.1.1. Metoclopramide 16.50.1.2. Pruclopride 16.50.2. Antiemetic Agents 16.50.2.1. Prochlorperazine 16.50.2.2. Ondansetron 16.50.3. Botulinum Toxin 16.50.4. Others 16.51. MalaysiaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 16.51.1. Hospitals 16.51.2. Homecare 16.51.3. Specialty Clinics 16.51.4. Others 16.52. MalaysiaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.52.1. Oral 16.52.2. Injectable 16.53. MalaysiaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.53.1. Hospital Pharmacies 16.53.2. Retail Pharmacies 16.53.3. Others 16.54. IndonesiaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.54.1. Compensated Gastroparesis 16.54.2. Gastric Failure 16.55. IndonesiaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 16.55.1. Medication 16.55.2. Surgery 16.56. IndonesiaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 16.56.1. Gastroprokinetic Agents 16.56.1.1. Metoclopramide 16.56.1.2. Pruclopride 16.56.2. Antiemetic Agents 16.56.2.1. Prochlorperazine 16.56.2.2. Ondansetron 16.56.3. Botulinum Toxin 16.56.4. Others 16.57. IndonesiaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 16.57.1. Hospitals 16.57.2. Homecare 16.57.3. Specialty Clinics 16.57.4. Others 16.58. IndonesiaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.58.1. Oral 16.58.2. Injectable 16.59. IndonesiaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.59.1. Hospital Pharmacies 16.59.2. Retail Pharmacies 16.59.3. Others 16.60. VietnamDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.60.1. Compensated Gastroparesis 16.60.2. Gastric Failure 16.61. VietnamDiabetic Gastroparesis Treatment Market Forecast, By Treatment 16.61.1. Medication 16.61.2. Surgery 16.62. VietnamDiabetic Gastroparesis Treatment Market Forecast, By Drugs 16.62.1. Gastroprokinetic Agents 16.62.1.1. Metoclopramide 16.62.1.2. Pruclopride 16.62.2. Antiemetic Agents 16.62.2.1. Prochlorperazine 16.62.2.2. Ondansetron 16.62.3. Botulinum Toxin 16.62.4. Others 16.63. VietnamDiabetic Gastroparesis Treatment Market Forecast, By End-Users 16.63.1. Hospitals 16.63.2. Homecare 16.63.3. Specialty Clinics 16.63.4. Others 16.64. VietnamDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.64.1. Oral 16.64.2. Injectable 16.65. VietnamDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.65.1. Hospital Pharmacies 16.65.2. Retail Pharmacies 16.65.3. Others 16.66. Rest of Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 16.66.1. Compensated Gastroparesis 16.66.2. Gastric Failure 16.67. Rest of Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Treatment 16.67.1. Medication 16.67.2. Surgery 16.68. Rest of Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Drugs 16.68.1. Gastroprokinetic Agents 16.68.1.1. Metoclopramide 16.68.1.2. Pruclopride 16.68.2. Antiemetic Agents 16.68.2.1. Prochlorperazine 16.68.2.2. Ondansetron 16.68.3. Botulinum Toxin 16.68.4. Others 16.69. Rest of Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By End-Users 16.69.1. Hospitals 16.69.2. Homecare 16.69.3. Specialty Clinics 16.69.4. Others 16.70. Rest of Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 16.70.1. Oral 16.70.2. Injectable 16.71. Rest of Asia Pacific Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 16.71.1. Hospital Pharmacies 16.71.2. Retail Pharmacies 16.71.3. Others 16.72. Asia Pacific Diabetic Gastroparesis Treatment Market Attractiveness Analysis 16.72.1. By Indication Type 16.72.2. By Treatment 16.72.3. By Drugs 16.72.4. By End-Users 16.72.5. By Route of Administration 16.72.6. By Distribution Channel 16.73. PEST Analysis 16.74. Key Trends 16.75. Key Developments 17. Middle East & Africa Diabetic Gastroparesis Treatment Market Analysis 17.1. Key Findings 17.2. Middle East & Africa Diabetic Gastroparesis Treatment Market Overview 17.3. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, By Indication Type 17.4. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 17.4.1. Compensated Gastroparesis 17.4.2. Gastric Failure 17.5. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, By Treatment 17.6. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Treatment 17.6.1. Medication 17.6.2. Surgery 17.7. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, By Drugs 17.8. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Drugs 17.8.1. Gastroprokinetic Agents 17.8.1.1. Metoclopramide 17.8.1.2. Pruclopride 17.8.2. Antiemetic Agents 17.8.2.1. Prochlorperazine 17.8.2.2. Ondansetron 17.8.3. Botulinum Toxin 17.8.4. Others 17.9. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, By End-Users 17.10. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By End-Users 17.10.1. Hospitals 17.10.2. Homecare 17.10.3. Specialty Clinics 17.10.4. Others 17.11. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, By Route of Administration 17.12. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 17.12.1. Oral 17.12.2. Injectable 17.13. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, By Distribution Channel 17.14. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 17.14.1. Hospital Pharmacies 17.14.2. Retail Pharmacies 17.14.3. Others 17.15. Middle East & Africa Diabetic Gastroparesis Treatment Market Value Share Analysis, by Country 17.16. Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, by Country 17.16.1. GCC 17.16.2. South Africa 17.16.3. Nigeria 17.16.4. Egypt 17.16.5. Rest of Middle East & Africa 17.17. Middle East & Africa Diabetic Gastroparesis Treatment Market Analysis, by Country 17.18. GCC Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 17.18.1. Compensated Gastroparesis 17.18.2. Gastric Failure 17.19. GCC Diabetic Gastroparesis Treatment Market Forecast, By Treatment 17.19.1. Medication 17.19.2. Surgery 17.20. GCC Diabetic Gastroparesis Treatment Market Forecast, By Drugs 17.20.1. Gastroprokinetic Agents 17.20.1.1. Metoclopramide 17.20.1.2. Pruclopride 17.20.2. Antiemetic Agents 17.20.2.1. Prochlorperazine 17.20.2.2. Ondansetron 17.20.3. Botulinum Toxin 17.20.4. Others 17.21. GCCDiabetic Gastroparesis Treatment Market Forecast, By End-Users 17.21.1. Hospitals 17.21.2. Homecare 17.21.3. Specialty Clinics 17.21.4. Others 17.22. GCC Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 17.22.1. Oral 17.22.2. Injectable 17.23. GCC Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 17.23.1. Hospital Pharmacies 17.23.2. Retail Pharmacies 17.23.3. Others 17.24. South Africa Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 17.24.1. Compensated Gastroparesis 17.24.2. Gastric Failure 17.25. South Africa Diabetic Gastroparesis Treatment Market Forecast, By Treatment 17.25.1. Medication 17.25.2. Surgery 17.26. South Africa Diabetic Gastroparesis Treatment Market Forecast, By Drugs 17.26.1. Gastroprokinetic Agents 17.26.1.1. Metoclopramide 17.26.1.2. Pruclopride 17.26.2. Antiemetic Agents 17.26.2.1. Prochlorperazine 17.26.2.2. Ondansetron 17.26.3. Botulinum Toxin 17.26.4. Others 17.27. South Africa Diabetic Gastroparesis Treatment Market Forecast, By End-Users 17.27.1. Hospitals 17.27.2. Homecare 17.27.3. Specialty Clinics 17.27.4. Others 17.28. South Africa Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 17.28.1. Oral 17.28.2. Injectable 17.29. South Africa Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 17.29.1. Hospital Pharmacies 17.29.2. Retail Pharmacies 17.29.3. Others 17.30. NigeriaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 17.30.1. Compensated Gastroparesis 17.30.2. Gastric Failure 17.31. NigeriaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 17.31.1. Medication 17.31.2. Surgery 17.32. NigeriaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 17.32.1. Gastroprokinetic Agents 17.32.1.1. Metoclopramide 17.32.1.2. Pruclopride 17.32.2. Antiemetic Agents 17.32.2.1. Prochlorperazine 17.32.2.2. Ondansetron 17.32.3. Botulinum Toxin 17.32.4. Others 17.33. NigeriaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 17.33.1. Hospitals 17.33.2. Homecare 17.33.3. Specialty Clinics 17.33.4. Others 17.34. NigeriaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 17.34.1. Oral 17.34.2. Injectable 17.35. NigeriaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 17.35.1. Hospital Pharmacies 17.35.2. Retail Pharmacies 17.35.3. Others 17.36. EgyptDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 17.36.1. Compensated Gastroparesis 17.36.2. Gastric Failure 17.37. EgyptDiabetic Gastroparesis Treatment Market Forecast, By Treatment 17.37.1. Medication 17.37.2. Surgery 17.38. EgyptDiabetic Gastroparesis Treatment Market Forecast, By Drugs 17.38.1. Gastroprokinetic Agents 17.38.1.1. Metoclopramide 17.38.1.2. Pruclopride 17.38.2. Antiemetic Agents 17.38.2.1. Prochlorperazine 17.38.2.2. Ondansetron 17.38.3. Botulinum Toxin 17.38.4. Others 17.39. EgyptDiabetic Gastroparesis Treatment Market Forecast, By End-Users 17.39.1. Hospitals 17.39.2. Homecare 17.39.3. Specialty Clinics 17.39.4. Others 17.40. EgyptDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 17.40.1. Oral 17.40.2. Injectable 17.41. EgyptDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 17.41.1. Hospital Pharmacies 17.41.2. Retail Pharmacies 17.41.3. Others 17.42. Rest of Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 17.42.1. Compensated Gastroparesis 17.42.2. Gastric Failure 17.43. Rest of Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Treatment 17.43.1. Medication 17.43.2. Surgery 17.44. Rest of Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Drugs 17.44.1. Gastroprokinetic Agents 17.44.1.1. Metoclopramide 17.44.1.2. Pruclopride 17.44.2. Antiemetic Agents 17.44.2.1. Prochlorperazine 17.44.2.2. Ondansetron 17.44.3. Botulinum Toxin 17.44.4. Others 17.45. Rest of Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By End-Users 17.45.1. Hospitals 17.45.2. Homecare 17.45.3. Specialty Clinics 17.45.4. Others 17.46. Rest of Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 17.46.1. Oral 17.46.2. Injectable 17.47. Rest of Middle East & Africa Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 17.47.1. Hospital Pharmacies 17.47.2. Retail Pharmacies 17.47.3. Others 17.48. Middle East & Africa Diabetic Gastroparesis Treatment Market Attractiveness Analysis 17.48.1. By Indication Type 17.48.2. By Treatment 17.48.3. By Drugs 17.48.4. By End-Users 17.48.5. By Route of Administration 17.48.6. By Distribution Channel 17.49. PEST Analysis 17.50. Key Trends 17.51. Key Developments 18. South America Diabetic Gastroparesis Treatment Market Analysis 18.1. Key Findings 18.2. South America Diabetic Gastroparesis Treatment Market Overview 18.3. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Indication Type 18.4. South America Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 18.4.1. Compensated Gastroparesis 18.4.2. Gastric Failure 18.5. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Treatment 18.6. South America Diabetic Gastroparesis Treatment Market Forecast, By Treatment 18.6.1. Medication 18.6.2. Surgery 18.7. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Drugs 18.8. South America Diabetic Gastroparesis Treatment Market Forecast, By Drugs 18.8.1. Gastroprokinetic Agents 18.8.1.1. Metoclopramide 18.8.1.2. Pruclopride 18.8.2. Antiemetic Agents 18.8.2.1. Prochlorperazine 18.8.2.2. Ondansetron 18.8.3. Botulinum Toxin 18.8.4. Others 18.9. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, By End-Users 18.10. South America Diabetic Gastroparesis Treatment Market Forecast, By End-Users 18.10.1. Hospitals 18.10.2. Homecare 18.10.3. Specialty Clinics 18.10.4. Others 18.11. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Route of Administration 18.12. South America Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 18.12.1. Oral 18.12.2. Injectable 18.13. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, By Distribution Channel 18.14. South America Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 18.14.1. Hospital Pharmacies 18.14.2. Retail Pharmacies 18.14.3. Others 18.15. South America Diabetic Gastroparesis Treatment Market Value Share Analysis, by Country 18.16. South America Diabetic Gastroparesis Treatment Market Forecast, by Country 18.16.1. Brazil 18.16.2. Mexico 18.16.3. Argentina 18.16.4. Rest of South America 18.17. South America Diabetic Gastroparesis Treatment Market Analysis, by Country 18.18. Brazil Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 18.18.1. Compensated Gastroparesis 18.18.2. Gastric Failure 18.19. Brazil Diabetic Gastroparesis Treatment Market Forecast, By Treatment 18.19.1. Medication 18.19.2. Surgery 18.20. Brazil Diabetic Gastroparesis Treatment Market Forecast, By Drugs 18.20.1. Gastroprokinetic Agents 18.20.1.1. Metoclopramide 18.20.1.2. Pruclopride 18.20.2. Antiemetic Agents 18.20.2.1. Prochlorperazine 18.20.2.2. Ondansetron 18.20.3. Botulinum Toxin 18.20.4. Others 18.21. BrazilDiabetic Gastroparesis Treatment Market Forecast, By End-Users 18.21.1. Hospitals 18.21.2. Homecare 18.21.3. Specialty Clinics 18.21.4. Others 18.22. Brazil Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 18.22.1. Oral 18.22.2. Injectable 18.23. Brazil Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 18.23.1. Hospital Pharmacies 18.23.2. Retail Pharmacies 18.23.3. Others 18.24. Mexico Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 18.24.1. Compensated Gastroparesis 18.24.2. Gastric Failure 18.25. Mexico Diabetic Gastroparesis Treatment Market Forecast, By Treatment 18.25.1. Medication 18.25.2. Surgery 18.26. Mexico Diabetic Gastroparesis Treatment Market Forecast, By Drugs 18.26.1. Gastroprokinetic Agents 18.26.1.1. Metoclopramide 18.26.1.2. Pruclopride 18.26.2. Antiemetic Agents 18.26.2.1. Prochlorperazine 18.26.2.2. Ondansetron 18.26.3. Botulinum Toxin 18.26.4. Others 18.27. Mexico Diabetic Gastroparesis Treatment Market Forecast, By End-Users 18.27.1. Hospitals 18.27.2. Homecare 18.27.3. Specialty Clinics 18.27.4. Others 18.28. Mexico Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 18.28.1. Oral 18.28.2. Injectable 18.29. Mexico Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 18.29.1. Hospital Pharmacies 18.29.2. Retail Pharmacies 18.29.3. Others 18.30. ArgentinaDiabetic Gastroparesis Treatment Market Forecast, By Indication Type 18.30.1. Compensated Gastroparesis 18.30.2. Gastric Failure 18.31. ArgentinaDiabetic Gastroparesis Treatment Market Forecast, By Treatment 18.31.1. Medication 18.31.2. Surgery 18.32. ArgentinaDiabetic Gastroparesis Treatment Market Forecast, By Drugs 18.32.1. Gastroprokinetic Agents 18.32.1.1. Metoclopramide 18.32.1.2. Pruclopride 18.32.2. Antiemetic Agents 18.32.2.1. Prochlorperazine 18.32.2.2. Ondansetron 18.32.3. Botulinum Toxin 18.32.4. Others 18.33. ArgentinaDiabetic Gastroparesis Treatment Market Forecast, By End-Users 18.33.1. Hospitals 18.33.2. Homecare 18.33.3. Specialty Clinics 18.33.4. Others 18.34. ArgentinaDiabetic Gastroparesis Treatment Market Forecast, By Route of Administration 18.34.1. Oral 18.34.2. Injectable 18.35. ArgentinaDiabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 18.35.1. Hospital Pharmacies 18.35.2. Retail Pharmacies 18.35.3. Others 18.36. Rest of South America Diabetic Gastroparesis Treatment Market Forecast, By Indication Type 18.36.1. Compensated Gastroparesis 18.36.2. Gastric Failure 18.37. Rest of South America Diabetic Gastroparesis Treatment Market Forecast, By Treatment 18.37.1. Medication 18.37.2. Surgery 18.38. Rest of South America Diabetic Gastroparesis Treatment Market Forecast, By Drugs 18.38.1. Gastroprokinetic Agents 18.38.1.1. Metoclopramide 18.38.1.2. Pruclopride 18.38.2. Antiemetic Agents 18.38.2.1. Prochlorperazine 18.38.2.2. Ondansetron 18.38.3. Botulinum Toxin 18.38.4. Others 18.39. Rest of South America Diabetic Gastroparesis Treatment Market Forecast, By End-Users 18.39.1. Hospitals 18.39.2. Homecare 18.39.3. Specialty Clinics 18.39.4. Others 18.40. Rest of South America Diabetic Gastroparesis Treatment Market Forecast, By Route of Administration 18.40.1. Oral 18.40.2. Injectable 18.41. Rest of South America Diabetic Gastroparesis Treatment Market Forecast, By Distribution Channel 18.41.1. Hospital Pharmacies 18.41.2. Retail Pharmacies 18.41.3. Others 18.42. South America Diabetic Gastroparesis Treatment Market Attractiveness Analysis 18.42.1. By Indication Type 18.42.2. By Treatment 18.42.3. By Drugs 18.42.4. By End-Users 18.42.5. By Route of Administration 18.42.6. By Distribution Channel 18.43. PEST Analysis 18.44. Key Trends 18.45. Key Developments 19. Company Profiles 19.1. Market Share Analysis, by Company 19.2. Competition Matrix 19.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 19.2.2. New Product Launches and Product Enhancements 19.2.3. Market Consolidation 19.2.3.1. M&A by Regions, Investment and Applications 19.2.3.2. M&A Key Players, Forward Integration and Backward Integration 19.3. Company Profiles: Key Players 19.3.1. Theravance Biopharma 19.3.1.1. Company Overview 19.3.1.2. Financial Overview 19.3.1.3. Product Portfolio 19.3.1.4. Business Strategy 19.3.1.5. Recent Developments 19.3.1.6. Development Footprint 19.3.2. Allergan 19.3.3. GlaxoSmithKline plc 19.3.4. Endologic 19.3.5. Evoke Pharma 19.3.6. Takeda Pharmaceutical Company Limited 19.3.7. Eli Lilly and Company 19.3.8. Vanda Pharmaceuticals 19.3.9. F. Hoffmann-La Roche Ltd 19.3.10. CINRX 19.3.11. Ironwood Pharmaceuticals, Inc. 19.3.12. ANI Pharmaceuticals, Inc. 19.3.13. Bausch Health 19.3.14. RHYTHM PHARMACEUTICALS, INC 19.3.15. Teva Pharmaceutical Industries Ltd 19.3.16. WOCKHARDT 19.3.17. Fresenius Kabi AG 19.3.18. Pfizer Inc 19.3.19. Ipca Laboratories Ltd 19.3.20. Vintage Labs 19.3.21. Others 20. Primary Key Insights